Companies › Hinova Pharmaceuticals
3 active drug programs in 3 registered trials: 1 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Gastroenterology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HC-1119 | – | Phase 3 | MCRPC | – |
| HP515 | – | Phase 2 | NAFLD (Non-alcoholic Fatty Liver Disease) | Dec 2026 |
| HP518 | – | Phase 1 | Metastatic Castration-resistant Prostate Cancer | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03851640 | HC-1119 | Phase 3 | MCRPC | Oncology | Sep 2025 |
| NCT06155084 | HP518 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Mar 2026 |
| NCT07308548 | HP515 | Phase 2 | NAFLD (Non-alcoholic Fatty Liver Disease) | Gastroenterology | Dec 2026 |
No annotated target.
–
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Xuanzhu Biopharmaceutical Institut de Recherches Internationales Servier (I.R.I.S.) Blue Earth Diagnostics Shenzhen TargetRx
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.